Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2015 1
2016 1
2017 1
2018 1
2019 1
2020 2
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

10 results
Results by year
Filters applied: . Clear all
Page 1
MYC, MYCL, and MYCN as therapeutic targets in lung cancer.
Massó-Vallés D, Beaulieu ME, Soucek L. Massó-Vallés D, et al. Expert Opin Ther Targets. 2020 Feb;24(2):101-114. doi: 10.1080/14728222.2020.1723548. Epub 2020 Feb 13. Expert Opin Ther Targets. 2020. PMID: 32003251 Review.
Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy.
Beaulieu ME, Jauset T, Massó-Vallés D, Martínez-Martín S, Rahl P, Maltais L, Zacarias-Fluck MF, Casacuberta-Serra S, Serrano Del Pozo E, Fiore C, Foradada L, Cano VC, Sánchez-Hervás M, Guenther M, Romero Sanz E, Oteo M, Tremblay C, Martín G, Letourneau D, Montagne M, Morcillo Alonso MÁ, Whitfield JR, Lavigne P, Soucek L. Beaulieu ME, et al. Among authors: masso valles d. Sci Transl Med. 2019 Mar 20;11(484):eaar5012. doi: 10.1126/scitranslmed.aar5012. Sci Transl Med. 2019. PMID: 30894502 Free PMC article.
Ibrutinib repurposing: from B-cell malignancies to solid tumors.
Massó-Vallés D, Jauset T, Soucek L. Massó-Vallés D, et al. Oncoscience. 2016 Jun 10;3(5-6):147-8. doi: 10.18632/oncoscience.310. eCollection 2016. Oncoscience. 2016. PMID: 27489860 Free PMC article. No abstract available.
Pancreatic cancer heterogeneity and response to Mek inhibition.
Pedersen K, Bilal F, Bernadó Morales C, Salcedo MT, Macarulla T, Massó-Vallés D, Mohan V, Vivancos A, Carreras MJ, Serres X, Abu-Suboh M, Balsells J, Allende E, Sagi I, Soucek L, Tabernero J, Arribas J. Pedersen K, et al. Among authors: masso valles d. Oncogene. 2017 Oct 5;36(40):5639-5647. doi: 10.1038/onc.2017.174. Epub 2017 Jun 5. Oncogene. 2017. PMID: 28581516
BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC.
Jauset T, Massó-Vallés D, Martínez-Martín S, Beaulieu ME, Foradada L, Fiorentino FP, Yokota J, Haendler B, Siegel S, Whitfield JR, Soucek L. Jauset T, et al. Among authors: masso valles d. Oncotarget. 2018 Apr 10;9(27):18734-18746. doi: 10.18632/oncotarget.24648. eCollection 2018 Apr 10. Oncotarget. 2018. PMID: 29721157 Free PMC article.
The Wnt signaling receptor Fzd9 is essential for Myc-driven tumorigenesis in pancreatic islets.
Zacarías-Fluck MF, Jauset T, Martínez-Martín S, Kaur J, Casacuberta-Serra S, Massó-Vallés D, Serrano Del Pozo E, Martín-Fernández G, González-Larreategui Í, López-Estévez S, Brown-Swigart L, Beaulieu ME, Whitfield JR, Madan B, Virshup DM, Evan GI, Soucek L. Zacarías-Fluck MF, et al. Among authors: masso valles d. Life Sci Alliance. 2021 Mar 2;4(5):e201900490. doi: 10.26508/lsa.201900490. Print 2021 May. Life Sci Alliance. 2021. PMID: 33653688 Free PMC article.
Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis.
Annibali D, Whitfield JR, Favuzzi E, Jauset T, Serrano E, Cuartas I, Redondo-Campos S, Folch G, Gonzàlez-Juncà A, Sodir NM, Massó-Vallés D, Beaulieu ME, Swigart LB, Mc Gee MM, Somma MP, Nasi S, Seoane J, Evan GI, Soucek L. Annibali D, et al. Among authors: masso valles d. Nat Commun. 2014 Aug 18;5:4632. doi: 10.1038/ncomms5632. Nat Commun. 2014. PMID: 25130259 Free PMC article.